Business Context and Reporting Period
Company: BioSig Technologies, Inc. (BSGM)
Filing Date: May 23, 2025 (Report Date: May 27, 2025)
Event: Entry into a Material Definitive Agreement (Share Purchase Agreement) to acquire Streamex Exchange Corporation ("Streamex").
Transaction Structure: BioSig will acquire all issued and outstanding shares of Streamex through a wholly-owned subsidiary (BST Sub ULC). The transaction is structured as a reverse merger/reorganization intended to qualify under Section 368(a) of the Internal Revenue Code.
Key Financial Metrics and Transaction Terms
Consideration: BioSig will issue an aggregate of 109,070,079 exchangeable shares in its subsidiary (BST Sub ULC) to Streamex shareholders.
Exchange Ratio: 2.05 Exchangeable Shares for each Streamex share purchased.
Ownership Structure Post-Closing:
- Initial Phase: Exchangeable Shares will not be exchangeable into more than 19.9% of BioSig's outstanding common stock (pre-transaction basis) to comply with Nasdaq listing rules.
- Post-Approval Phase: Upon stockholder approval of "Parent Stockholder Matters," Streamex shareholders will be entitled to receive shares equal to 75% of BioSig's fully diluted common stock. Existing BioSig shareholders will retain 25%.
- Contingency: If stockholder approval is not obtained within six months of closing, the Exchange Ratio will adjust from 1.0 to 1.25.
Financial Data: The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for either company.
Material Changes and Corporate Governance
Executive Leadership Changes:
- Outgoing: Anthony Amato will resign as Chief Executive Officer (CEO).
- Incoming: Henry McPhie (Co-founder and CEO of Streamex) will be appointed CEO of BioSig.
- Board Composition: The board will consist of six members: four designated by BioSig (including Mr. Amato) and two by Streamex (Mr. McPhie and Morgan Lekstrom). Morgan Lekstrom will also be appointed Chairman. Frederick D. Hrkac will resign from the board.
Executive Compensation (Anthony Amato):
- Severance pay of $400,000, payable in equal installments over eight months.
- Full acceleration of all outstanding equity awards (vested and exercisable).
- Extended post-resignation exercise period for stock options.
- Right of First Refusal ("Right to Place") for the Company to purchase Mr. Amato's securities for 12 months.
Capital Structure Changes: Creation of a new series of "Special Voting Preferred Stock" (one share) held by a Trustee to exercise voting rights on behalf of Exchangeable Shareholders. This stock ranks senior to common stock in liquidation but carries no dividends.
Guidance, Outlook, and Risks
Outlook: The transaction is intended to qualify as a tax-free reorganization. The closing is contingent upon the satisfaction or waiver of conditions set forth in the Share Purchase Agreement.
Regulatory and Listing Risks:
- The Company must file an initial listing application for its common stock if required by Nasdaq's change of control rules.
- Stockholder approval is required to unlock the full 75% ownership stake for Streamex shareholders; failure to obtain this within six months triggers an adjustment to the exchange ratio.
Unusual Items: The issuance of securities is relying on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D.
Investor Verification Checklist
- Verify the exact number of pre-transaction outstanding shares of BioSig to calculate the precise dilution impact of the 109,070,079 exchangeable shares.
- Confirm the status of the "Parent Stockholder Matters" vote and the timeline for the six-month approval window.
- Review the full text of the Share Purchase Agreement (Exhibit 2.1) for specific closing conditions and termination fees.
- Assess the financial health and regulatory standing of Streamex Exchange Corporation, as it will become the primary operating asset.
- Monitor Nasdaq's response to the change of control and the potential requirement for a new listing application.